Clinical Trials Browser

OTHER × Observational × osimertinib × Clear all

NCT06477055 2026-04-13

RAISE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06538038 2026-03-27

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07491211 2026-03-27

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06613633 2025-04-20

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT04965701 2023-11-13

FLOWER

EGF-R Positive Non-Small Cell Lung Cancer

NCT04391283 2023-03-17

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Carcinoma, Non-Small-Cell Lung

NCT03790397 2022-06-03

OSIREX

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04575415 2020-10-20

BELLA

NSCLC

NCT03532698 2020-07-23

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung